文献速递脑血管病神经重症与神经感染

凝血酶原复合物与NOAC相关脑出血血肿扩大关系

Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage.
PubMed 文献 · Ann Neurol · 2018-01-01

该回顾性多中心队列纳入190例NOAC相关脑出血患者,分析凝血酶原复合物(PCC)与血肿扩大的关联。结果显示PCC给药与血肿扩大率降低无显著关联,而4小时内收缩压<160mmHg与血肿扩大比例降低显著相关。

要点

  • PCC给药与NOAC相关脑出血血肿扩大率降低无显著关联。
  • 4小时内收缩压<160mmHg与血肿扩大比例降低显著相关。
  • PCC对住院死亡和3个月功能结局均无影响。

核心结论

  • 与血压控制不同,PCC给药与NOAC相关脑出血血肿扩大率降低无显著关联。

研究设计与样本

  • 回顾性队列研究,纳入德国19个神经科2011至2015年190例NOAC相关脑出血患者。
  • 主要结局分析纳入146例有随访影像的患者。

主要发现

  • 146例中49例(33.6%)发生血肿扩大。
  • 血肿扩大相关参数为4小时内血压≥160mmHg及因子Xa抑制剂脑出血入院时抗Xa水平。
  • PCC给药与血肿扩大率降低无显著关联(NOAC:RR=1.150,95%CI=0.632-2.090;因子Xa抑制剂:RR=1.057,95%CI=0.565-1.977)。
  • 4小时内收缩压<160mmHg与血肿扩大比例降低显著相关(RR=0.598,95%CI=0.365-0.978)。
  • PCC给药对出院时及3个月死亡率和功能结局均无影响。

关键数值与推荐

  • 血肿扩大定义为随访影像显示血肿增大。
  • 功能结局采用改良Rankin量表评估3个月时状态。
  • PCC给药与血肿扩大关联不受PCC剂量或至影像/治疗时间间隔影响。

临床怎么用

  • NOAC相关脑出血应重视4小时内收缩压控制在<160mmHg。
  • 不应仅基于血肿扩大预防目的常规使用PCC。
  • 因子Xa抑制剂相关脑出血需探索新的止血逆转策略。

局限性

  • 回顾性研究设计。
  • 主要结局分析仅纳入146例有随访影像的患者。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate parameters associated with hematoma enlargement in non-vitamin K antagonist oral anticoagulant (NOAC)-related intracerebral hemorrhage (ICH). METHODS: This retrospective cohort study includes individual patient data for 190 patients with NOAC-associated ICH over a 5-year period (2011-2015) at 19 departments of neurology across Germany. Primary outcome was the association of prothrombin complex concentrate (PCC) administration with hematoma enlargement. Subanalyses were calculated for blood pressure management and its association with the primary outcome. Secondary outcomes include associations with in-hospital mortality and functional outcome at 3 months assessed using the modified Rankin Scale. RESULTS: The study population for analysis of primary and secondary outcomes consisted of 146 NOAC-ICH patients with available follow-up imaging. Hematoma enlargement occurred in 49/146 (33.6%) patients with NOAC-related ICH. Parameters associated with hematoma enlargement were blood pressure ≥ 160mmHg within 4 hours and-in the case of factor Xa inhibitor ICH-anti-Xa levels on admission. PCC administration prior to follow-up imaging was not significantly associated with a reduced rate of hematoma enlargement either in overall NOAC-related ICH or in patients with factor Xa inhibitor intake (NOAC: risk ratio [RR] = 1.150, 95% confidence interval [CI] = 0.632-2.090; factor Xa inhibitor: RR = 1.057, 95% CI = 0.565-1.977), regardless of PCC dosage given or time interval until imaging or treatment. Systolic blood pressure levels < 160mmHg within 4 hours after admission were significantly associated with a reduction in the proportion of patients with hematoma enlargement (RR = 0.598, 95% CI = 0.365-0.978). PCC administration had no effect on mortality and functional outcome either at discharge or at 3 months. INTERPRETATION: In contrast to blood pressure control, PCC administration was not associated with a reduced rate of hematoma enlargement in NOAC-related ICH. Our findings support the need of further investigations exploring new hemostatic reversal strategies for patients with factor Xa inhibitor-related ICH. Ann Neurol 2018;83:186-196.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Gerner ST, Kuramatsu JB, Sembill JA, et al. Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage. Ann Neurol. 2018. PMID: 29314216. doi:10.1002/ana.25134

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。